Publications

Pre-clinical study of mRNA encoding an antibody against chikungunya virus protected against infection, showed dose-dependent protein expression and no dose-limiting toxicities in vivo.

Modified mRNA vaccines delivered with a proprietary Moderna LNP show enhanced tolerability and comparable immunogenicity relative to legacy LNP.

This preclinical study with a LNP-formulated, modified mRNA vaccine demonstrates 100% survival and higher protective antibody titers than previously observed with viral vector vaccines.

Results in non-human primates characterize the response of immune-suppressive cells to vaccination, expanding our understanding of the mechanisms underlying vaccine immunogenicity versus reactogenicity.

This research demonstrates that LNP-formulated mRNA vaccines can induce protection against viral placental and fetal damage in mouse models, critical for vaccines against viruses that exhibit vertical transmission.

This in vivo research demonstrates that a mRNA vaccine encoding components of a subviral particle can prevent disease.

This review highlights the potential for RNA cancer immunotherapies, including mRNA applications in cancer vaccines and immune modulation.

Local delivery of mRNA encoding the secreted cytokines IL-23 and IL-36γ and the membrane-bound T-cell co-stimulator OX40L induced a broad immune response promoting tumor regression in both injected lesions and distant un-injected tumors in mice.

Data from a Phase 1a/b study of mRNA encoding for vascular endothelial growth factor A (VEGF-A) shows tolerability, protein expression and protein pharmacology in human subjects and its potential for use as a regenerative therapeutic.

In mouse models, the intradermal administration of mRNA encoding for VEGF-A can induce a localized, sustained, and reproducible biological response, including blood vessel formation and oxygenation to accelerate diabetic wound healing.

(This publication is the work of a Moderna strategic collaborator and Moderna assumes no responsibility for the information or statements therein).

This foundational paper establishes that direct injection of modified mRNA in mice can induce local physiological changes and could be an effective approach for regenerative therapeutics.

This pre-clinical study demonstrates that repeat dose mRNA therapy substantially improved survival and growth and ameliorated biochemical abnormalities with no adverse effects in multiple MMA mouse models, supporting long-term treatment with mRNA therapeutics.

Preclinical data in a mouse model of citrin deficiency reinforces the potential of mRNA-based therapies to treat rare metabolic disorders.

Administration of mRNA encoding human α-Gal demonstrate pre-clinical proof-of-concept, across species, of a potential systemic mRNA therapy for the treatment of Fabry disease.

Rapid onset of effect with mRNA therapeutics is demonstrated in the acute setting, imparting hepatic enzymatic activity with repeat dosing in small and large animals.

This study elucidates the fundamental mechanism of accelerated blood clearance of LNPs, informing improved designs for nanoparticle delivery systems.

This study describes a novel analytical method to characterize mRNA sequences with great specificity and to detect minor sequence impurities to inform technical development of mRNA therapeutics.

Non-human primate and rodent studies demonstrate the potential for repeat dosing of mRNA safely and at therapeutically relevant levels with proprietary Moderna lipids.

In vivo studies with systemic delivery of modified mRNA in an industry standard LNP demonstrate therapeutic levels of protein expression and predictable pharmacology and toxicology.

This chapter highlights recent advances in the delivery of nucleotide therapeutics and their application to mRNA therapeutics.

This paper explores the molecular mechanisms through which modified nucleosides can promote translation efficiency, which is critical to designing potent mRNA therapeutics.